Can A Cancer Drug Originated In China Be A Success In The U.S.?
Fruquintinib may not be the best test case for bringing a homegrown China medicine to the U.S.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: John LaMattina, Contributor Tags: ETR:BAYN NYSE:RHHBY Source Type: news